Literature DB >> 20619448

Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial.

Richard J McManus1, Jonathan Mant, Emma P Bray, Roger Holder, Miren I Jones, Sheila Greenfield, Billingsley Kaambwa, Miriam Banting, Stirling Bryan, Paul Little, Bryan Williams, F D Richard Hobbs.   

Abstract

BACKGROUND: Control of blood pressure is a key component of cardiovascular disease prevention, but is difficult to achieve and until recently has been the sole preserve of health professionals. This study assessed whether self-management by people with poorly controlled hypertension resulted in better blood pressure control compared with usual care.
METHODS: This randomised controlled trial was undertaken in 24 general practices in the UK. Patients aged 35-85 years were eligible for enrolment if they had blood pressure more than 140/90 mm Hg despite antihypertensive treatment and were willing to self-manage their hypertension. Participants were randomly assigned in a 1:1 ratio to self-management, consisting of self-monitoring of blood pressure and self-titration of antihypertensive drugs, combined with telemonitoring of home blood pressure measurements or to usual care. Randomisation was done by use of a central web-based system and was stratified by general practice with minimisation for sex, baseline systolic blood pressure, and presence or absence of diabetes or chronic kidney disease. Neither participants nor investigators were masked to group assignment. The primary endpoint was change in mean systolic blood pressure between baseline and each follow-up point (6 months and 12 months). All randomised patients who attended follow-up visits at 6 months and 12 months and had complete data for the primary outcome were included in the analysis, without imputation for missing data. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN17585681.
FINDINGS: 527 participants were randomly assigned to self-management (n=263) or control (n=264), of whom 480 (91%; self-management, n=234; control, n=246) were included in the primary analysis. Mean systolic blood pressure decreased by 12.9 mm Hg (95% CI 10.4-15.5) from baseline to 6 months in the self-management group and by 9.2 mm Hg (6.7-11.8) in the control group (difference between groups 3.7 mm Hg, 0.8-6.6; p=0.013). From baseline to 12 months, systolic blood pressure decreased by 17.6 mm Hg (14.9-20.3) in the self-management group and by 12.2 mm Hg (9.5-14.9) in the control group (difference between groups 5.4 mm Hg, 2.4-8.5; p=0.0004). Frequency of most side-effects did not differ between groups, apart from leg swelling (self-management, 74 patients [32%]; control, 55 patients [22%]; p=0.022).
INTERPRETATION: Self-management of hypertension in combination with telemonitoring of blood pressure measurements represents an important new addition to control of hypertension in primary care. FUNDING: Department of Health Policy Research Programme, National Coordinating Centre for Research Capacity Development, and Midlands Research Practices Consortium. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619448     DOI: 10.1016/S0140-6736(10)60964-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  189 in total

1.  CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.

Authors:  Monique Mendelson; Isabelle Vivodtzev; Renaud Tamisier; David Laplaud; Sonia Dias-Domingos; Jean-Philippe Baguet; Laurent Moreau; Christian Koltes; Léonidas Chavez; Gilles De Lamberterie; Frédéric Herengt; Patrick Levy; Patrice Flore; Jean-Louis Pépin
Journal:  Sleep       Date:  2014-11-01       Impact factor: 5.849

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  Using a modified technology acceptance model to evaluate healthcare professionals' adoption of a new telemonitoring system.

Authors:  Marie Pierre Gagnon; Estibalitz Orruño; José Asua; Anis Ben Abdeljelil; José Emparanza
Journal:  Telemed J E Health       Date:  2011-11-14       Impact factor: 3.536

4.  4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary.

Authors:  Boris N Mankovsky
Journal:  Diabetes Technol Ther       Date:  2011-10-04       Impact factor: 6.118

5.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

6.  RCGP Research Paper of the Year 2014: partnership with patients is an important theme in primary care research.

Authors:  Chris Salisbury
Journal:  Br J Gen Pract       Date:  2015-11       Impact factor: 5.386

7.  Hypertension: Rest before blood pressure measurement: a lesson from SPRINT.

Authors:  Rajiv Agarwal
Journal:  Nat Rev Nephrol       Date:  2016-01-25       Impact factor: 28.314

8.  Using mHealth for the management of hypertension in UK primary care: an embedded qualitative study of the TASMINH4 randomised controlled trial.

Authors:  Sabrina Grant; James Hodgkinson; Claire Schwartz; Peter Bradburn; Marloes Franssen; Fd Richard Hobbs; Sue Jowett; Richard J McManus; Sheila Greenfield
Journal:  Br J Gen Pract       Date:  2019-08-29       Impact factor: 5.386

9.  Health coaching to improve hypertension treatment in a low-income, minority population.

Authors:  David Margolius; Thomas Bodenheimer; Heather Bennett; Jennifer Wong; Victoria Ngo; Guillermo Padilla; David H Thom
Journal:  Ann Fam Med       Date:  2012 May-Jun       Impact factor: 5.166

Review 10.  The Role of Home Blood Pressure Telemonitoring for Blood Pressure Control.

Authors:  Chan Joo Lee; Sungha Park
Journal:  Pulse (Basel)       Date:  2016-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.